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Abstract
Background: Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3 (SCA3), is an autosomal dominant
neurodegenerative disorder of late onset, which is caused by a CAG repeat expansion in the coding region of the
ATXN3 gene. This disease presents clinical heterogeneity, which cannot be completely explained by the size of the
repeat tract. MJD presents extrapyramidal motor signs, namely Parkinsonism, more frequently than the other
subtypes of autosomal dominant cerebellar ataxias. Although Parkinsonism seems to segregate within MJD families,
only a few MJD patients develop parkinsonian features and, therefore, the clinical and genetic aspects of these rare
presentations remain poorly investigated. The main goal of this work was to describe two MJD patients displaying
the parkinsonian triad (tremor, bradykinesia and rigidity), namely on what concerns genetic variation in Parkinson’s
disease (PD) associated loci (PARK2, LRRK2, PINK1, DJ-1, SNCA, MAPT, APOE, and mtDNA tRNAGln T4336C).
Case presentation: Patient 1 is a 40 year-old female (onset at 30 years of age), initially with a pure parkinsonian
phenotype (similar to the phenotype previously reported for her mother). Patient 2 is a 38 year-old male (onset at
33 years of age), presenting an ataxic phenotype with parkinsonian features (not seen either in other affected
siblings or in his father). Both patients presented an expanded ATXN3 allele with 72 CAG repeats. No PD mutations
were found in the analyzed loci. However, allelic variants previously associated with PD were observed in DJ-1 and
APOE genes, for both patients.
Conclusions: The present report adds clinical and genetic information on this particular and rare MJD
presentation, and raises the hypothesis that DJ-1 and APOE polymorphisms may confer susceptibility to the
parkinsonian phenotype in MJD.
Background
Autosomal dominant cerebellar ataxias (ADCA) consti-
tute a heterogeneous group of neurodegenerative disor-
ders, which involve, besides other systems, the
extrapyramidal system in a highly variable manner.
Within this group is Machado-Joseph disease (MJD;
MIM #109150), also known as spinocerebellar ataxia
type 3 (SCA3), that presents extrapyramidal motor signs
(EPS) more frequently than the other subtypes of ADCA
[1]. Even within MJD, the EPS may vary, sometimes
with marked dystonic postures, others with isolated par-
kinsonian features or even, though rarely, with the par-
kinsonian triad (resting tremor, bradykinesia and
rigidity) [2]. Although the causative mutation of MJD is
known to be an expansion of a CAG repeat motif (con-
sensually more than 52 repeats) in the coding region of
the ATXN3 gene [3], the size of the of the repetitive
tract does not completely explain the clinical heteroge-
neity observed in this disorder, namely concerning the
presence of EPS.
There are only a few reports of a Parkinson’s disease
(PD)-like phenotype in molecularly confirmed MJD
patients [4-6], and thus this particular MJD phenotype
remains poorly documented, namely from the genetic
point of view. The cases reported in the literature
showed an initial phenotype indistinguishable from PD
and a levodopa positive response. Only after several
years of progression the characteristic features of MJD,
namely cerebellar signs, were observed. The parkinso-
nian phenotype has been suggested to be more common
* Correspondence: mcbettencourt@uac.pt
1Center of Research in Natural Resources (CIRN), University of the Azores,
Ponta Delgada, Portugal
Full list of author information is available at the end of the article
Bettencourt et al. BMC Neurology 2011, 11:131
http://www.biomedcentral.com/1471-2377/11/131
© 2011 Bettencourt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
in MJD patients of African descent, although rare in
those of European origin [7].
MJD phenotypes with EPS, particularly those with a
PD-like phenotype, may result from epistatic effects of
variants in other loci. As primary candidates are PD
associated loci, namely PARK2, LRRK2, PINK1, DJ-1,
SNCA, MAPT, and APOE (e.g. [8-10]). Variation in
mitochondrial DNA (mtDNA) has also been shown to
have an impact on neurodegenerative diseases’ pheno-
type, and the tRNAGln T4336C mutation was previously
associated with Alzheimer’s disease (AD) and PD [11].
The main goal of this work was to describe two unre-
lated MJD patients displaying the parkinsonian triad, for
which the genetic variation (mutations and/or poly-
morphisms) in PD associated loci was investigated.
Case Presentation
Out of a series of 70 molecularly confirmed MJD
patients from the Azores Islands (Portugal), from whom
DNA samples were available (extracted from blood sam-
ples, which were collected after obtaining written
informed consent), two patients presenting the parkinso-
nian triad, and belonging to distinct MJD families (one
from São Miguel Island and other from Graciosa Island),
were identified.
Patient 1
Patient 1 is a 40 year-old female patient (Figure 1; III-4).
At the age of 30 years (Table 1), she noticed slowness of
movements. At examination, she had a poor mimic and
marked bradykinesia. She responded well to L-dopa,
which she maintained for 8 years. At this time she was
hospitalized because of neurological aggravation and
depression. She presented, besides a prominent parkin-
sonian syndrome with frequent on-off phenomena, cere-
bellar dysarthria and general incoordination, axial and
upper limbs dystonia, upwards gaze limitation with
upwards gaze nystagmus, generalized hyperreflexia and
bilateral Babinski sign, as well as marked gait ataxia.
Her mother (Figure 1; II-3) also had exhibited a parkin-
sonian phenotype. By the age of 34, she noticed diffi-
culty in walking and in the fine movements of the
hands. First examined at 36, she had bradykinesia,
including amimia, bilateral hypertonia, without tremor,
nor incoordination. The gait was purely parkinsonian,
with small steps and no balance of the arms. She
responded well to L-dopa, reaching a normal neurologi-
cal examination under 300 mg + 75 mg of the inhibitor.
Examined 12 years later, she was still under L-dopa
treatment. Besides her parkinsonian syndrome and
extreme diskynesias, she had a deep depression, a mod-
erate gait and lower limbs’ ataxia, cerebellar dysarthria,
and marked upwards gaze limitation. The maternal
grandfather of Patient 1 (Figure 1; I-1) had an onset at
63 years of age with slowly progressive gait ataxia, fol-
lowed by dysarthria, diplopia and dysphagia. Examined
the first time with 8 years of evolution, he had upwards
gaze limitation and horizontal squint, moderate peroneal
atrophy with generalized arreflexia, plantars in flexion,
slight dysmetria in the upper limbs, marked dysmetria
Figure 1 Pedigree of Patient 1. Black filled figures represent MJD
patients; Crosshatched figures represent MJD patients with a
parkinsonian phenotype.
Table 1 Characteristics of Patient 1 and Patient 2
Characteristics Patient 1 Patient 2
Age at Onset 30 33
Onset Mode Pure PD signs PD plus cerebellar
signs?
Family history for PD
features
Mother and
grandfather
NP
ATXN3 (CAG)n tract
length
Normal Allele 14 29
Expanded Allele 72 72
PARK2 Gene Mutations NP NP
LRRK2 Gene Mutations NP NP
PINK1 Gene Mutations NP NP
DJ-1 Gene
Mutations NP NP
Polymorphisms
g.168_185del Del/Del Ins/Del
rs7517357 T/T C/T
rs2641116 G/G T/G
rs56327722 A/A G/A
SNCA Gene
REP1 261/261 261/261
MAPT Gene
rs242557 A/G G/G
Haplotype H1/H2 H2/H2
APOE Gene
genotype ε2/ε3 ε2/ε3
mtDNA
T4336C mutation NP NP
Haplogroup H H
NP - Not present
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in the lower limbs and ataxic gait possible with unilat-
eral support. Four years later mild Parkinson’s signs
were observed, with resting tremor in the upper limbs
and bilateral rigidity. He died two years later aged 77
years.
Patient 2
Patient 2 is a 38 year-old male patient (Figure 2: II-16).
He reported complaints of left hand’s tremor since he
was 33 years old. In neurological examination at the age
of 35 years, he presented slight tremor of the left hand
and of the L-lower limb. There was a cog-wheel rigidity
of the left side, slight ataxia, hyperreflexia and right
Babinski sign. The EPS responded consistently to L-
dopa. His MRI was normal. His father (Figure 2: I-1)
was only observed after 18 years of disease progression
(reported onset at 42 years old), but did not present
EPS. Furthermore, none of the remaining affected sib-
lings (Figure 2: II-4, II-9, and II-12) present parkinso-
nian features.
Molecular analysis
The ATXN3 (CAG)n tract size was determined as pre-
viously described [12]. All the exons and exon-introns
boundaries of PARK2, LRRK2, PINK1 and DJ-1 genes
were amplified by PCR. The resulting PCR products
were purified by Exo-SAP treatment (GE Healthcare)
and sequenced using the BigDye® Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems). Multiplex
Ligation-Dependent Probe Amplification (MLPA) was
used, according to Djarmati et al. [13], to search for
large deletions or duplications in PARK2, PINK1 and
DJ-1. The SNCA REP1 allele-length variants were geno-
typed as previously described [9]. In MAPT locus, a
SNP (rs242557) was genotyped by a custom Taqman
assay according to the manufacturer’s specifications, and
its genotype was used to infer MAPT haplotypes. The
APOE genotypes were determined according to Betten-
court et al. [14]. The mtDNA haplogroup was estab-
lished as previously described by Santos et al. [15], and
the region encompassing the T4336C mutation was
amplified by PCR, according to Ramos et al. [16]. PCR
products were purified using the JETQUICK PCR Purifi-
cation Spin Kit (Genomed) and sequenced, using the
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems), according to the manufacturer’s
specifications.
Both patients presented 72 CAG repeats in their
expanded ATXN3 allele (Table 1), which corresponds to
the mode for the expanded alleles in the Azorean MJD
series [17]. In PARK2, LRRK2, PINK1, DJ-1 and mtDNA
tRNAGln, no known pathogenic mutations were detected
in the analyzed regions (Table 1). Several polymorph-
isms were found at the DJ-1 gene (Table 1). Results for
the SNCA REP1, MAPT and APOE loci, as well as for
the mtDNA haplogroup, are shown in Table 1.
Although MJD presents EPS more frequently than the
other ADCAs, the manifestation of the parkinsonian
triad is rare, being present in less than 3% of the ana-
lyzed MJD series. Even though the two studied cases are
distinct, the grandfather-mother-daughter transmission
in the family of Patient 1, and the heterogeneity pre-
sented by the family of Patient 2, suggests a supporting
genetic background, e.g. modifier gene(s).
Mutations in the PARK2 gene have been described as
the most frequent in the cases of early onset PD [18].
However, none of the studied patients presented muta-
tions in this gene. Similarly, no mutations were identi-
fied in LRRK2, PINK1 and DJ-1 genes, or in position
4336 of mtDNA.
Given the fact that both patients belong to a typically
European mtDNA haplogroup [15], the hypothesis of an
African background, in which the parkinsonian pheno-
type seems more common [7], was not supported, at
least in terms of maternal origin.
Association studies have shown that certain alleles of
the SNCA REP1 locus, as well as the presence of two
copies of MAPT H1, increase the risk of PD (e.g. [9,10]).
In the patients analyzed, however, the homozygousity
for the 261 allele (the commonest among Caucasians
[9]), and the presence of at least one MAPT H2 was
confirmed.
Although previous studies [19,20] failed to find an
association between DJ-1 g.168_185del polymorphism
Figure 2 Pedigree of Patient 2. Black filled figures represent MJD patients; Crosshatched figures represent MJD patients with a parkinsonian
phenotype.
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and PD, De Marco et al. [21], using a larger series of PD
patients, have reported that several DJ-1 polymorphisms,
including those observed in the present study and
reported in Table 1, are significantly associated with PD.
The APOE ε2 has been associated with increased risk
of sporadic PD [8], and with an earlier onset of PD (e.g.
[22]). The studied patients presented both the APOE ε2/
ε3 genotype.
In non-Parkinsonian patients (N = 55) from the Azor-
ean MJD series (data not shown), the DJ-1 g.168_185del
was found in 23% of the alleles, not differing from the
frequency of this deletion in other non-Parkinsonian
Caucasian populations studied previously (e.g. [19-21]).
The APOE ε2 allele was present in only 4% of the
alleles, which corresponds to a lower frequency than the
one previously reported for this allele in the general
Azorean population [14]. Besides the two Parkinsonian
MJD patients studied here, only 2 additional Azorean
patients (non-Parkinsonian) carry both the DJ-1
g.168_185del and the APOE ε2 allele.
Conclusions
The present report, in these two MJD patients, adds
information on this rare phenotype, by allowing a dee-
per knowledge of the clinical and genetic variation pre-
sent in such particular cases. Analysis of both pedigrees
supports a genetic background influence. Although we
cannot conclude on the presence of associations by
studying only two Parkinsonian patients, the present
results are in agreement with previous studies on Par-
kinson’s disease. The implication of these findings, on
what concerns a possible epistatic effect of the DJ-1
g.168_185del and the APOE ε2 allele on the MJD phe-
notype deserves to be tested, using an appropriate study
design, namely on what concerns adequate sized parkin-
sonian MJD series (presently unavailable, to our
knowledge).
Consent
Written consent was obtained from both patients for the
publication of this case report. A copy of written con-
sent is available for review by the Editor-in-Chief of this
journal.
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